Celentyx Ltd

Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas.

We provide bespoke pre-clinical/early discovery phase laboratory services to support academic groups, pharmaceutical and biotechnology companies in their R&D studies and biomarker research.

The Company
- Founded in 2015 and Privately owned
- Operating out of Biocity, Nottingham
- Experienced Management team with track record of delivering complex scientific projects and peer reviewed
international publications
- Completed over 40 successful scientific projects in collaboration with over 25 sponsors
- Links with leading UK Universities
- Fully serviced laboratory with Specialised personnel
- National and International partners

Our USP:
- Dynamic CRO offering specialist skills with over 30 years of combined experience
- Therapeutic area expertise
- Value for money
- Efficient time management, thanks to our streamlined structure
- Flexibility in operations to suit our client needs.
- Customised service and support focused on customer retention and satisfaction
- Logistics support

Our vision is 'Integrated scientific services; from experimental conception to project delivery'​.

Our mission is:
- To revolutionise drug discovery research by providing integrated, cost-effective laboratory services including assay design consultancy, logistics support, bespoke high quality assay development/validation and data analysis.
- To be a responsible and trusted laboratory-based CRO partner with Quality, Flexibility, Reliability and Customer support as our indispensable asset.

Redoxis is a preclinical boutique CRO specializing on inflammation and autoimmune conditions. We provide in vivo, ex vivo and in vitro preclinical efficacy and MoA studies. We have a fully equipped lab with capacity to perform a wide range of cell based assays as well as immunology assays to provide you everything form MoA studies to PK and in vivo efficacy studies.

Cerba Research is the merge of Barc Lab, Histalim and Cerba Xpert. All 3 entities are part of the Cerba HealthCare group and have decided to join forces under one name.

Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.

From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.

Synovo GmbH is a Tübingen based pharmaceutical discovery services company with a focus on inflammation and innate immunity providing services in:

Medicinal Chemistry
Pharmacology
Cell Engineering
Peptide Modification

Synovo's main pharmacology activities are based on assays and models for the selection of drug candidates with improved properties of Absorption, Disposition, Metabolism and Elimination (ADME or DMPK). Synovo establishes these parameters using human derived cells, proteins and systems wherever feasible to ensure the relevance of its data to use in man.

Synovo is engaged in projects in the fields of anti-inflammatory and immune suppressive drug optimization on behalf of clients from the pharmaceutical industry. Synovo is also working in partnership with public sector laboratories to improve its systems and extend its technologies to protein and nucleic acid drugs.

Synovo is self-sustaining through its service business and it has always run profitably. The core of the services offering are pharmacological studies which it conducts mainly for biotech and mid-size companies. In addition, support functions like formulation chemistry and analytics enable more complex development studies.

In parallel, Synovo uses its skills and facilities to conduct innovative research in collaboration with partners throughout the world. This has resulted in various drug candidates being developed for immune-oncology applications and more recently, inflammatory bowel disease and infection. Drug development is a long and costly process, so Synovo has also worked on projects which are easier to develop.

Based in Tübingen, home of one of the most prestigious and best known Universities in Germany, Synovo GmbH benefits from access to cutting edge technology, highly skilled staff and a magnificent location over looking the Swabian Alps.

Taros Chemicals GmbH & Co. KG, an independent, privately owned contract research organization based in Dortmund, Germany, has been serving the chemistry needs of pharmaceutical, chemical and biotech companies since its inception in 1999. A forerunner in the early German biotech scene, Taros can claim more than 13,000 syntheses, research and process chemistry projects delivered to-date to an increasingly expanding and diverse base of global customers.

In its state-of-the-art facilities in Dortmund's prestigious BioMedizinZentrum (BMZ), the hub of top ranking biotech organizations, Taros'​ team of highly creative and skilled scientists, aided by its state-of-the-art laboratory facilities, are wholly committed to solving a wide range of customers'​ R&D problems in innovative drug discovery, medicinal chemistry and classical synthetic chemistry. Their collective knowledge and experience in industrial organic chemistry, span a period of over 160 years, and in active drug discovery, around 60 years, covering the full spectrum, from big pharma to biotechnology. Taros is active today in therapeutic areas which include oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious diseases, in all small-molecule target classes.

Our company's mission is to enhance the quality of human lives by providing advanced and innovative chemistry-driven technologies to our customers R&D endeavors in the global marketplace. We strive hard to provide creative, holistic and cost-effective solutions with the highest level of quality, reliability and integrity. We continuously endorse loyalty and commitment in our employees, inspiring them to provide exceptional value to our customers'​ R&D processes, by anticipating hurdles before they arise, by foreseeing potential cost and lead time reductions, and most importantly, by facilitating their competitive and "early to market"​ advantage.